
usd jul pm et
summari lead develop manufactur provid analyt instrument
complex servic life scienc drug discoveri industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
broad product line geograph coverag span
life scienc health care industri market
singl custom account total
revenu reduc risk view balanc
intens competit industri compani
oper howev cutting-edg technolog
requir remain relev present risk
technolog obsolesc fact
present signific integr execut risk
organ revenu growth yoy
averag previou four
quarter rate still impress
view especi light year
gener econom growth slowdown
intern market gener
revenu despit macro headwind
life scienc earn acceler
achiev organ sale growth yoy
oper profit growth yoy
robust demand biopharmaceut
china sale also continu grow rapidli
around yoy despit slow econom
growth new -china tariff
impos past year
believ overal long-term demand outlook
busi remain strong
expect organ revenu growth
adjust pre-tax incom per share
grew yoy materi faster sale
margin basi point leverag also
improv annual ebita-to-interest
coverag june
prior-year period leav us
optimist pursu
next year
like dual strategi invest heavili
intern innov organ growth
pursu leverag scale
invest new technolog
unriv view estim
combin capital-expenditure spend surpass
next three largest competitor combin
 front execut reward
formula use conserv debt acquir
improv margin de-lever
also possess key advantag
allow continu increas market share
view includ lack single-sourc
compon help avoid supplier
cost increas better peer
escal tariff environ
think creat sticki custom
target price ep
estim histor forward price-to-earnings
averag reflect on-going shift toward
profit higher growth segment
declin leverag risk view includ
slump end market particularli biopharma
 cut escal
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
board
corpor overview thermo fisher scientif lead provid life scienc tool
servic broad array end market includ pharma biotech compani academ
govern institut diagnost health care compani industri appli scienc
compani product servic includ laboratori analyt instrument biochem reagent
laboratori medic consum softwar servic research analysi discoveri
diagnosi think largest compani within marketplac broadest product offer
geograph coverag
life scienc solut sale provid reagent instrument consum use
biolog medic research discoveri product new drug vaccin well diagnosi
diseas life scienc solut includ four primari busi bioscienc genet scienc
clinic next-gener sequenc bioproduct
analyt instrument sale provid instrument consum softwar servic
use rang applic laboratori product line field segment
includ three primari busi chromatographi mass spectrometri chemic analysi
materi structur analysi
specialti diagnost sale offer wide rang diagnost test kit reagent cultur media
instrument associ product custom health care clinic pharmaceut industri
food safeti laboratori specialti diagnost product gener use increas speed
accuraci diagnos improv qualiti cost-effect patient care
laboratori product servic sale laboratori supplier offer virtual everyth
need oper lab combin self-manufactur sourc product segment
also includ comprehens offer outsourc servic use biopharmaceut firm drug
develop clinic trial logist commerci drug manufactur
corpor strategi think greatest strength lie industry-lead product breadth
across segment view creat one-stop shop effect allow research organ larg
small conveni order divers product need time cost-effect manner
one sourc exampl pharma custom start purchas mass spectromet
like eventu pitch sale rep save lab could gener switch
lab product supplier initi relationship may lead provid manufactur
servic compani downstream depart think breadth
product servic help gain market share concentr competitor way
continu expand product portfolio extens intern develop
extern growth via acquisit estim combin capital-expenditure roughli
line next three largest competitor combin also proven extrem effect
streamlin oper acquir firm execut billion worth acquisit sinc
end steadili increas adjust pre-tax incom margin period recent
notabl acquisit includ august acquisit patheon billion septemb
acquisit fei compani billion march acquisit affymetrix billion
februari acquisit billion
patheon ebita margin earn interest tax amort stand-alon
busi lower appear execut cost synergi overal ebita
margin maintain august acquisit also see strong
revenu growth opportun patheon clinic trial servic bioproduct technolog
expect improv margin scale grow
competit landscap life scienc tool servic marketplac highli fragment
competit think may competit advantag peer due purchas
power oper leverag broad product offer geograph coverag publicli trade competitor
includ water corp among privat held
firm vwr corpor primari competitor
financi trend sale increas billion billion repres
three-year compound annual growth rate compound-annual-growth-rate prolif acquir acquisit
aid sale growth adjust pre-tax incom per share rose
repres compound-annual-growth-rate estim ebita-to-interest coverag improv
last major acquisit patheon think repres
return conserv leverag level leav well-posit anoth major acquisit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc juli technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year see balanc posit
neg factor posit earn
growth view strong growth
 public fund medic research
demand growth emerg market expect
factor partial off-set lower
biopharmaceut spend higher
oper cost due tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect growth
mark major acceler averag
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
publicly-fund client expect softer
demand biopharmaceut firm year
ahead estim
total spend
pharmaceut biotech
biopharmaceut compani grew
annual averag yet spend look
slow saw modest yoy
declin larg swath biopharma
typic flow lst firm suppli
depart research tool softwar
well contract servic clinic drug
trial commerci manufactur
accordingli think slowdown
biopharmaceut invest
headwind lst sub-industri
anoth neg factor expect
lst earn growth
recent escal trade tariff particularli
 china analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
brought lower profit mani
busi think shift relat
tariff impos -china trade
septemb rais product
cost instrument maker
escal may addit
china largest intern market
instrument maker think new
tariff drove major slowdown china
sale growth end sight
current trade disput expect tariff
continu pressur sale growth
oper margin sub-industri
 life scienc
drop
year-to-d juli lst
rose gain
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain buy opinion share thermo fisher
scientif inc keep target
ep estim materi histor forward price-to-earnings averag
expect continu margin expans de-lever rais ep
estim ep
vs beat consensu organ revenu growth slow
yoy averag previou four quarter
view impress light econom growth slowdown sever
intern market year life scienc oper profit
show sign slow howev organ revenu growth yoy
oper profit growth yoy life scienc continu strength
china sale grew mid-teen yoy despit new tariff drove total
oper profit growth yoy adjust foreign exchang impact
expect ep grow strong demand outlook improv oper
effici ampl dri powder /colin scarola
et cfra maintain buy opinion share thermo fisher scientif
inc keep target ep
estim long-term averag forward price-to-earnings expect above-averag
ep growth lower ep estim keep
ep vs beat forecast report
strong view top-lin growth yoy driven solid growth across
four oper segment life scienc total revenu analyt
instrument fastest grow yoy respect
driven continu robust demand biopharmaceut custom
china-bas buyer china sale growth total remain strong yoy
expect growth market also improv pre-tax
incom margin roughli bp yoy expect improv margin trend
continu patheon acquisit integr
major plant machineri invest made harvest
pm et cfra maintain buy opinion share thermo fisher
scientif inc lift target price
ep estim maintain -- materi
five-year forward price-to-earnings averag think premium valuat
histor averag justifi due declin leverag earn mix
significantli shift past five year toward faster grow higher
margin busi ratio annual adjust oper incom interest
expens period averag march
significantli higher improv leverag free
cash flow bolt acquisit share repurchas
addit back fastest grow highest margin segment
life scienc contribut oper incom compar
on-going shift toward profit higher growth busi line
warrant higher valuat view reflect higher return capit
faster earn growth /colin scarola
scientif inc keep target
slightli above-p averag ep estim expect
above-averag growth initi ep estim ep
vs beat estim report strong quarter
view top-lin growth yoy fuel patheon
acquisit last year acceler organ growth segment
especi impress acceler organ sale growth life
scienc yoy believ indic
grow market share rapidli grow field especi import
given life scienc largest segment profit total
also improv oper margin bp yoy led success sg
contain effort expect margin improv next year
strong track record streamlin second year larg
acquisit case patheon next year /colin scarola
et cfra maintain buy opinion share thermo fisher
scientif inc lift target
ep estim -- well-abov five-year forward price-to-earnings averag
think above-averag valuat justifi busi
shift significantli past five year faster grow higher
margin busi exampl fastest grow highest
margin segment life scienc contribut oper incom
gener shift help overal oper margin
improv basi point firm organ
revenu growth averag annual versu
expect organ growth remain elev strong demand
rapidli grow biopharmaceut field earn mix
increasingli shift toward profit high growth busi higher
price-to-earnings multipl justifi view reflect higher return capit
et cfra maintain buy opinion share thermo fisher
scientif inc lift target
ep estim -- histor forward price-to-earnings averag
expect above-averag long-term growth maintain ep
estim ep vs beat consensu sale grew
yoy even stronger organ growth broad base four
segment achiev organ growth better life scienc
oper incom perform especi well yoy organ sale growth
saw robust demand biopharmaceut client addit despit
linger concern tariff china sale total grew
robust yoy indic strong competit posit countri
view adjust pre-tax incom grew yoy materi faster
sale pre-tax margin improv bp yoy think premium valuat
warrant due strong demand outlook improv oper
effici ampl dri powder /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
